Maud Beillat

633 total citations
28 papers, 492 citations indexed

About

Maud Beillat is a scholar working on Psychiatry and Mental health, Economics and Econometrics and Epidemiology. According to data from OpenAlex, Maud Beillat has authored 28 papers receiving a total of 492 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Psychiatry and Mental health, 9 papers in Economics and Econometrics and 6 papers in Epidemiology. Recurrent topics in Maud Beillat's work include Health Systems, Economic Evaluations, Quality of Life (9 papers), Schizophrenia research and treatment (9 papers) and Herpesvirus Infections and Treatments (4 papers). Maud Beillat is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (9 papers), Schizophrenia research and treatment (9 papers) and Herpesvirus Infections and Treatments (4 papers). Maud Beillat collaborates with scholars based in France, United Kingdom and Denmark. Maud Beillat's co-authors include Laurence Serradell, Christophe Sapin, Patrizio Pezzotti, Antonio Volpi, Luigi Naldi, Monica Merito, Leonardo Emberti Gialloreti, Antonio Gatti, Anna Eramo and Ross A. Baker and has published in prestigious journals such as PLoS ONE, Schizophrenia Research and BMC Psychiatry.

In The Last Decade

Maud Beillat

24 papers receiving 482 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Maud Beillat France 10 214 204 93 89 67 28 492
Na Jin China 10 29 0.1× 273 1.3× 2 0.0× 18 0.2× 55 0.8× 38 398
Anne Crochard France 10 425 2.0× 66 0.3× 22 0.2× 13 0.1× 14 0.2× 23 628
Marc Brodsky United States 8 83 0.4× 53 0.3× 2 0.0× 9 0.1× 63 0.9× 23 308
Deborah Lehman United States 11 149 0.7× 217 1.1× 5 0.1× 40 0.6× 30 503
Gerardo A. Zavala United Kingdom 10 45 0.2× 68 0.3× 38 0.4× 14 0.2× 38 335
J. H. J. Bor Netherlands 9 52 0.2× 113 0.6× 134 1.4× 2 0.0× 8 0.1× 9 373
Reshma Kaushik India 11 58 0.3× 42 0.2× 2 0.0× 24 0.3× 10 0.1× 30 392
Israel Krieger Israel 11 31 0.1× 86 0.4× 17 0.2× 33 0.5× 21 287
Elizabeth Khaykin United States 6 35 0.2× 105 0.5× 18 0.2× 4 0.1× 6 235
Ian Hislop Australia 10 65 0.3× 73 0.4× 10 0.1× 29 0.3× 9 0.1× 28 465

Countries citing papers authored by Maud Beillat

Since Specialization
Citations

This map shows the geographic impact of Maud Beillat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maud Beillat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maud Beillat more than expected).

Fields of papers citing papers by Maud Beillat

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maud Beillat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maud Beillat. The network helps show where Maud Beillat may publish in the future.

Co-authorship network of co-authors of Maud Beillat

This figure shows the co-authorship network connecting the top 25 collaborators of Maud Beillat. A scholar is included among the top collaborators of Maud Beillat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maud Beillat. Maud Beillat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Raverot, Gérald, Philippe Chanson, Brigitte Delemer, et al.. (2025). Cost-utility analysis of second line acromegaly treatment in France. Annales d Endocrinologie. 86(5). 101811–101811.
3.
Perdrizet, Johnna, et al.. (2025). Impact of delaying PCV20 implementation in France’s pediatric national immunization program: A population-based Markov model. Infectious Diseases Now. 55(5). 105084–105084. 1 indexed citations
4.
Galactéros, Frederic, Olivier Ethgen, & Maud Beillat. (2023). Modeling the public health impact of voxelotor in the management of sickle cell disease in France. PLoS ONE. 18(9). e0291211–e0291211. 2 indexed citations
5.
6.
Alzaid, Aus, et al.. (2020). Burden of disease and costs associated with type 2 diabetes in emerging and established markets: systematic review analyses. Expert Review of Pharmacoeconomics & Outcomes Research. 21(4). 785–798. 43 indexed citations
7.
8.
Potkin, Steven G., Jean‐Yves Loze, Carlos Forray, et al.. (2017). Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning in schizophrenia: A post-hoc analysis of the QUALIFY study. PLoS ONE. 12(8). e0183475–e0183475. 6 indexed citations
9.
Potkin, Steven G., Jean‐Yves Loze, Carlos Forray, et al.. (2017). Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate. International Clinical Psychopharmacology. 32(3). 147–154. 19 indexed citations
10.
Sapin, Christophe, Ann Hartry, Siddhesh Kamat, et al.. (2016). Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis. Drugs in Context. 5. 1–8. 8 indexed citations
11.
Potkin, Steven G., Jean‐Yves Loze, Carlos Forray, et al.. (2016). Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate. The International Journal of Neuropsychopharmacology. 20(1). pyw093–pyw093. 21 indexed citations
12.
Sapin, Christophe, et al.. (2015). Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.. PubMed. 18(4). 185–200. 8 indexed citations
13.
Sapin, Christophe, et al.. (2015). Pharmacoeconomic Evaluation of Aripiprazole Once-Monthly Versus Paliperidone Palmitate in the UK: Findings From Qualify. Value in Health. 18(7). A410–A411. 2 indexed citations
14.
Naber, Dieter, Karina Hansen, Carlos Forray, et al.. (2015). Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophrenia Research. 168(1-2). 498–504. 118 indexed citations
15.
Lachaîne, Jean, et al.. (2014). Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada. BMC Psychiatry. 14(1). 16–16. 8 indexed citations
16.
Lachaîne, Jean, et al.. (2014). Cost-effectiveness of asenapine in the treatment of schizophrenia in Canada. Journal of Medical Economics. 17(4). 296–304. 9 indexed citations
17.
Gialloreti, Leonardo Emberti, Monica Merito, Patrizio Pezzotti, et al.. (2010). Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: A retrospective, population-based study. BMC Infectious Diseases. 10(1). 230–230. 140 indexed citations
18.
Mick, Gérard, F Simón, S. Pinchinat, et al.. (2010). Évaluation de l’incidence du zona, de la proportion des douleurs post-zostériennes, et des coûts associés dans la population française de 50 ans ou plus. Revue d Épidémiologie et de Santé Publique. 58(6). 393–401. 31 indexed citations
19.
Schiffner-Rohe, Julia, et al.. (2010). Ressourcenverbrauch und Kosten von Herpes zoster und postherpetischer Neuralgie in Deutschland. Gesundheitsökonomie & Qualitätsmanagement. 16(4). 216–223. 4 indexed citations
20.
Pouvourville, Gérard de, et al.. (2008). Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: The EPHESUS study. Archives of cardiovascular diseases. 101(9). 515–521. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Na Jin Breakdown of academic impact, for papers by Anne Crochard Breakdown of academic impact, for papers by Marc Brodsky Breakdown of academic impact, for papers by Deborah Lehman Breakdown of academic impact, for papers by Gerardo A. Zavala Breakdown of academic impact, for papers by J. H. J. Bor Breakdown of academic impact, for papers by Reshma Kaushik Breakdown of academic impact, for papers by Israel Krieger Breakdown of academic impact, for papers by Elizabeth Khaykin Breakdown of academic impact, for papers by Ian Hislop
Rankless by CCL
2026